Horm Metab Res 2008; 40(7): 507-509
DOI: 10.1055/s-2008-1062722
Short Communication

© Georg Thieme Verlag KG Stuttgart · New York

Intrapancreatic Adipocyte Deposition in a Mouse Model of the Metabolic Syndrome

F. Ülgen 1 , W. A. Scherbaum 1 , H.-J. Partke 2 , S. R. Bornstein 3 , S. Schinner 1
  • 1Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düsseldorf, Germany
  • 2German Diabetes Center, German Diabetes Research Institute, Düsseldorf, Germany
  • 3Department of Medicine, Carl Gustav Carus University of Dresden, Germany
Further Information

Publication History

received 29.08.2007

accepted 13.02.2008

Publication Date:
14 April 2008 (online)

Introduction

Obesity is a major risk factor for the development of insulin resistance and type 2 diabetes mellitus [1]. However, due to reactive hyperinsulinemia only a minority of obese and insulin-resistant individuals develop overt diabetes mellitus. The mechanisms causing hyperinsulinemia are not fully understood, but several studies have demonstrated that adipocytes are able to secret signaling molecules to act on β-cells [2]. In line with this, our previous findings have identified Wnt-signaling molecules derived from adipocytes to regulate β-cell proliferation and insulin secretion [3]. However, it is not yet clear whether local intrapancreatic adipocyte depots exist, possibly allowing for paracrine actions of adipocyte-derived hormones. Therefore, the aim of this study was to investigate the presence of local adipocyte deposition within the pancreas of wild-type (C57BL/6) and New Zealand Obese (NZO) mice, the latter representing a model for the metabolic syndrome [4].

In this study we found the deposition of ectopic adipocytes in the pancreas of obese, hyperinsulinemic NZO mice. Furthermore, we showed the proximity of adipocytes to pancreatic islets, potentially allowing for paracrine effects.

References

  • 1 Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR. Horm Metab Res. 2006;  38 437-441
  • 2 Rhodes CJ. Science. 2005;  307 380-384
  • 3 Schinner S, Ülgen F, Papewalis C, Schott M, Woelk A, Vidal-Puig A, Scherbaum WA. Diabetologia. 2008;  51 147-154
  • 4 Leiter EH, Reifsnyder PC, Flurkey K, Partke HJ, Junger E, Herberg L. Diabetes. 1998;  47 1287-1295
  • 5 Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Surv Synth Pathol Res. 1985;  4 110-125
  • 6 Lamounier-Zepter V, Rotthoff T, Ansurudeen I, Kopprasch S, Scherbaum WA, Ehrhart-Bornstein M, Bornstein SR. Horm Metab Res. 2006;  38 471-475
  • 7 Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP. Diabetes. 2004;  53 160-165
  • 8 Fischer-Posovszky P, Wabitsch M, Hochberg Z. Horm Metab Res. 2007;  39 314-321
  • 9 Kamari Y, Grossman E, Oron-Herman M, Peleg E, Shabtay Z, Shamiss A, Sharabi Y. Horm Metab Res. 2007;  39 384-388
  • 10 Olsen TS. Acta Pathol Microbiol Scand. 1978;  86A 367-373

Correspondence

S. SchinnerMD 

Department of Endocrinology, Diabetes and Rheumatology

University Hospital Düsseldorf

Moorenstr. 5

40225 Düsseldorf

Germany

Phone: +49/211/811 78 10

Fax: +49/211/811 78 60

Email: sven.schinner@uni-duesseldorf.de

    >